Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
Press Release: Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
Apogee Therapeutics Insider Sold Shares Worth $1,904,841, According to a Recent SEC Filing
Don't Ignore The Insider Selling In Apogee Therapeutics
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
Express News | Apogree Therapeutics Shares Are Trading Higher After the Company Announced Its Initiated Dosing of Its Clinical Trail for APG990
Express News | Apogee Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial For APG990, A Novel, Subcutaneous Half-life Extended Monoclonal Antibody Targeting OX40L, Which Is Being Developed Initially For Atopic Dermatitis
Express News | Apogee Therapeutics Inc - to Initiate Apg777 and Apg990 Trial in 2025
Express News | Apogee Therapeutics Inc - Expects Apg990 Interim Data in 2025
Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg990, Its Novel Half-Life Extended Ox40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
BofA Securities Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $80
Apogee Therapeutics: Advancing With Novel Combo Therapies in Inflammation and Immunology Markets
Express News | Apogee Therapeutics - Sales Agreement Prospectus Covering Offering of up to $300 Mln of Common Stock That May Be Issued Under Agreement
Express News | Apogee Therapeutics Inc Files for Mixed Shelf - SEC Filing
Apogee Therapeutics, Inc. (APGE) Receives a Buy From TD Cowen
Apogee Therapeutics | 10-Q: Q2 2024 Earnings Report
Apogee Therapeutics' Q2 Net Loss Widens
Express News | Apogee Therapeutics: Phase 1 Apg808 Trial on Track for 4Q 2024 Interim Data Readout
Apogee Therapeutics Research & Development Expenses $33.2M >APGE
Express News | Apogee Therapeutics: Phase 1 Apg990 Hv Clinical Trial Set to Start Ahead of Schedule in 3Q 2024